en
Scientific article
Open access
English

Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension

Published inBMC Cardiovascular Disorders, vol. 17, no. 1, 177
Publication date2017
Abstract

Despite the increased risk for pulmonary hypertension in children with Down syndrome, the response to treatment with targeted therapies for pulmonary hypertension in these patients is not well characterized. The Sildenafil in Treatment-naive children, Aged 1-17 years, with pulmonary arterial hypertension (STARTS-1) trial was a dose-ranging study of the short-term efficacy and safety of oral sildenafil in children with pulmonary arterial hypertension. We assessed the safety and efficacy of oral sildenafil in children with Down syndrome and pulmonary arterial hypertension.

Keywords
  • Administration
  • Oral
  • Adolescent
  • Antihypertensive Agents/administration & dosage/adverse effects
  • Arterial Pressure/drug effects
  • Child
  • Child
  • Preschool
  • China
  • Down Syndrome/complications/diagnosis
  • Female
  • Humans
  • Hypertension
  • Pulmonary/diagnosis/drug therapy/etiology/physiopathology
  • Infant
  • Male
  • Pulmonary Artery/drug effects/physiopathology
  • Sildenafil Citrate/administration & dosage/adverse effects
  • Time Factors
  • Treatment Outcome
  • Vascular Resistance/drug effects
  • Vasodilator Agents/administration & dosage/adverse effects
Citation (ISO format)
BEGHETTI, Maurice, RUDZINSKI, Andrzej, ZHANG, Min. Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension. In: BMC Cardiovascular Disorders, 2017, vol. 17, n° 1, p. 177. doi: 10.1186/s12872-017-0569-3
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1471-2261
384views
125downloads

Technical informations

Creation09/05/2018 12:16:00 PM
First validation09/05/2018 12:16:00 PM
Update time03/15/2023 8:37:15 AM
Status update03/15/2023 8:37:14 AM
Last indexation01/17/2024 3:29:58 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack